129 related articles for article (PubMed ID: 21512394)
21. Phase I/II study of S-1 combined with irinotecan for metastatic advanced gastric cancer.
Inokuchi M; Yamashita T; Yamada H; Kojima K; Ichikawa W; Nihei Z; Kawano T; Sugihara K
Br J Cancer; 2006 Apr; 94(8):1130-5. PubMed ID: 16570038
[TBL] [Abstract][Full Text] [Related]
22. A Phase II study of S-1 and irinotecan combination therapy in previously treated patients with advanced non-small cell lung cancer.
Ikemura S; Naoki K; Yasuda H; Kawada I; Yoda S; Terai H; Sato T; Ishioka K; Arai D; Ohgino K; Kamata H; Miyata J; Kabata H; Betsuyaku T; Soejima K
Jpn J Clin Oncol; 2015 Apr; 45(4):356-61. PubMed ID: 25612761
[TBL] [Abstract][Full Text] [Related]
23. Phase II/III study of second-line chemotherapy comparing irinotecan-alone with S-1 plus irinotecan in advanced gastric cancer refractory to first-line treatment with S-1 (JACCRO GC-05).
Tanabe K; Fujii M; Nishikawa K; Kunisaki C; Tsuji A; Matsuhashi N; Takagane A; Ohno T; Kawase T; Kochi M; Yoshida K; Kakeji Y; Ichikawa W; Chin K; Terashima M; Takeuchi M; Nakajima T
Ann Oncol; 2015 Sep; 26(9):1916-1922. PubMed ID: 26109630
[TBL] [Abstract][Full Text] [Related]
24. Phase I/II trial of irinotecan and S-1 combination chemotherapy as a second-line treatment for advanced colorectal cancer.
Takii Y; Yamazaki T; Okada T; Tani T; Funakoshi K; Maruyama S; Hasegawa J; Akazawa K; Hatakeyama K;
Chemotherapy; 2013; 59(5):338-43. PubMed ID: 24820531
[TBL] [Abstract][Full Text] [Related]
25. A phase II study of neoadjuvant combination chemotherapy with docetaxel, cisplatin, and S-1 for locally advanced resectable gastric cancer: nucleotide excision repair (NER) as potential chemoresistance marker.
Hirakawa M; Sato Y; Ohnuma H; Takayama T; Sagawa T; Nobuoka T; Harada K; Miyamoto H; Sato Y; Takahashi Y; Katsuki S; Hirayama M; Takahashi M; Ono M; Maeda M; Takada K; Hayashi T; Sato T; Miyanishi K; Takimoto R; Kobune M; Hirata K; Kato J
Cancer Chemother Pharmacol; 2013 Mar; 71(3):789-97. PubMed ID: 23338051
[TBL] [Abstract][Full Text] [Related]
26. A randomized phase II trial of pemetrexed plus irinotecan (ALIRI) versus leucovorin-modulated 5-FU plus irinotecan (FOLFIRI) in first-line treatment of locally advanced or metastatic colorectal cancer.
Underhill C; Goldstein D; Gorbounova VA; Biakhov MY; Bazin IS; Granov DA; Hossain AM; Blatter J; Kaiser C; Ma D
Oncology; 2007; 73(1-2):9-20. PubMed ID: 18334829
[TBL] [Abstract][Full Text] [Related]
27. [A phase II prospective randomized controlled trial of weekly paclitaxel combined with S-1 or fluorouracil for advanced gastric carcinoma].
Huang DZ; Xiong JP; Xu N; Yan Z; Zhuang ZX; Yu Z; Wan HP; Zhang Y; Deng T; Zheng RS; Guo ZQ; Hu CH; Wang ML; Yu ZH; Yao Y; Meng JC; Ba Y
Zhonghua Zhong Liu Za Zhi; 2012 Nov; 34(11):865-8. PubMed ID: 23291139
[TBL] [Abstract][Full Text] [Related]
28. A randomized phase II selection trial in patients with advanced/recurrent gastric cancer: Trial for Advanced Stomach Cancer (TASC).
Morita S; Baba H; Tsuburaya A; Takiuchi H; Matsui T; Maehara Y; Sakamoto J
Jpn J Clin Oncol; 2007 Jun; 37(6):469-72. PubMed ID: 17584825
[TBL] [Abstract][Full Text] [Related]
29. Activity of S-1 in advanced or recurrent gastric cancer patients after failure of prior chemotherapy, including irinotecan + cisplatin or fluorouracil (except S-1).
Ono A; Boku N; Onozawa Y; Hironaka S; Fukutomi A; Yasui H; Yamazaki K; Yoshino T; Taku K; Kojima T
Jpn J Clin Oncol; 2009 May; 39(5):332-5. PubMed ID: 19318372
[TBL] [Abstract][Full Text] [Related]
30. Phase II study of S-1, docetaxel and cisplatin combination chemotherapy in patients with unresectable metastatic gastric cancer.
Sato Y; Takayama T; Sagawa T; Takahashi Y; Ohnuma H; Okubo S; Shintani N; Tanaka S; Kida M; Sato Y; Ohta H; Miyanishi K; Sato T; Takimoto R; Kobune M; Yamaguchi K; Hirata K; Niitsu Y; Kato J
Cancer Chemother Pharmacol; 2010 Sep; 66(4):721-8. PubMed ID: 20041328
[TBL] [Abstract][Full Text] [Related]
31. [A clinical case of lymph node recurrence after resection of gastric cancer successfully treated by combination chemotherapy with irinotecan and cisplatin].
Fukunaga H; Endo W; Fujie Y; Shimizu K; Toyoda Y; Yoshioka A; Yoshioka S; Hojou S; Ota H; Maeura Y
Gan To Kagaku Ryoho; 2010 Nov; 37(12):2418-20. PubMed ID: 21224592
[TBL] [Abstract][Full Text] [Related]
32. Phase I study of combination therapy with S-1 and docetaxel (TXT) for advanced or recurrent gastric cancer.
Yoshida K; Hirabayashi N; Takiyama W; Ninomiya M; Takakura N; Sakamoto J; Nishiyama M; Toge T
Anticancer Res; 2004; 24(3b):1843-51. PubMed ID: 15274365
[TBL] [Abstract][Full Text] [Related]
33. Phase II study of docetaxel and S-1 combination therapy for advanced or recurrent gastric cancer.
Yoshida K; Ninomiya M; Takakura N; Hirabayashi N; Takiyama W; Sato Y; Todo S; Terashima M; Gotoh M; Sakamoto J; Nishiyama M
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3402-7. PubMed ID: 16740764
[TBL] [Abstract][Full Text] [Related]
34. [A case of advanced gastric cancer treated with S-1 and S-1/paclitaxel showing complete response twice].
Matsuyama J; Naitou A; Hiraki M; Matsumoto S; Hashimoto K; Yokoyama S; Morita S; Morimoto T; Fukushima Y; Nishishou I; Nomura T; Sasaki Y
Gan To Kagaku Ryoho; 2009 Nov; 36(12):2297-9. PubMed ID: 20037401
[TBL] [Abstract][Full Text] [Related]
35. Phase I study of bevacizumab combined with irinotecan and S-1 as second-line chemotherapy in patients with advanced colorectal cancer.
Kusaba H; Esaki T; Kishimoto J; Uchino K; Arita S; Kumagai H; Mitsugi K; Akashi K; Baba E
Cancer Chemother Pharmacol; 2013 Jan; 71(1):29-34. PubMed ID: 23228984
[TBL] [Abstract][Full Text] [Related]
36. Combination of low-dose docetaxel and standard-dose S-1 for the treatment of advanced gastric cancer: efficacy, toxicity, and potential predictive factor.
Cui Y; Li Q; Yu Y; Chen Y; Feng Y; Wang Y; Liu T
Cancer Chemother Pharmacol; 2013 Jan; 71(1):145-52. PubMed ID: 23064955
[TBL] [Abstract][Full Text] [Related]
37. Phase I/II study of S-1 combined with biweekly irinotecan chemotherapy in previously treated advanced non-small cell lung cancer.
Goya H; Kuraishi H; Koyama S; Ichiyama T; Yoshiike F; Hirai K; Agatsuma T; Tateishi K; Kanda S; Yamamoto H; Kubo K; Koizumi T
Cancer Chemother Pharmacol; 2012 Nov; 70(5):691-7. PubMed ID: 22941346
[TBL] [Abstract][Full Text] [Related]
38. [Therapeutic strategy for type 4 gastric cancer from the clinical oncologist standpoint].
Sasaki T; Koizumi W; Higuchi K; Ishido K; Ae T; Nakatani K; Katada C; Tanabe S; Saigenji K
Gan To Kagaku Ryoho; 2007 Jul; 34(7):988-92. PubMed ID: 17637532
[TBL] [Abstract][Full Text] [Related]
39. Sequential paclitaxel followed by tegafur and uracil (UFT) or S-1 versus UFT or S-1 monotherapy as adjuvant chemotherapy for T4a/b gastric cancer (SAMIT): a phase 3 factorial randomised controlled trial.
Tsuburaya A; Yoshida K; Kobayashi M; Yoshino S; Takahashi M; Takiguchi N; Tanabe K; Takahashi N; Imamura H; Tatsumoto N; Hara A; Nishikawa K; Fukushima R; Nozaki I; Kojima H; Miyashita Y; Oba K; Buyse M; Morita S; Sakamoto J
Lancet Oncol; 2014 Jul; 15(8):886-93. PubMed ID: 24954805
[TBL] [Abstract][Full Text] [Related]
40. Irinotecan plus S-1 versus S-1 in patients with previously treated recurrent or metastatic esophageal cancer (ESWN 01): a prospective randomized, multicenter, open-labeled phase 3 trial.
Huang J; Xu B; Liu Y; Huang J; Lu P; Ba Y; Wu L; Bai Y; Zhang S; Feng J; Cheng Y; Li J; Wen L; Yuan X; Ma C; Hu C; Fan Q; Wang X
Cancer Commun (Lond); 2019 Apr; 39(1):16. PubMed ID: 30940189
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
